5yvd: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
<StructureSection load='5yvd' size='340' side='right' caption='[[5yvd]], [[Resolution|resolution]] 2.70Å' scene=''> | <StructureSection load='5yvd' size='340' side='right' caption='[[5yvd]], [[Resolution|resolution]] 2.70Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5yvd]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5YVD OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5YVD FirstGlance]. <br> | <table><tr><td colspan='2'>[[5yvd]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Mers Mers]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5YVD OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5YVD FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5yvd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5yvd OCA], [http://pdbe.org/5yvd PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5yvd RCSB], [http://www.ebi.ac.uk/pdbsum/5yvd PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5yvd ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5yvd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5yvd OCA], [http://pdbe.org/5yvd PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5yvd RCSB], [http://www.ebi.ac.uk/pdbsum/5yvd PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5yvd ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Non-structural protein 15 (Nsp15) encoded by coronavirus (CoV) is a uridylate specific endoribonuclease (NendoU) that plays an essential role in the life cycle of the virus. Structural information of this crucial protein from the Middle East respiratory syndrome (MERS) CoV, which is lethally pathogenic and has caused severe respiratory diseases worldwide, is lacking. Here, we report the crystal structure of MERS-CoV Nsp15 at a 2.7 A resolution and perform the relevant biochemical assays to study how NendoU activity is regulated. Although the overall structure is conserved, MERS-CoV Nsp15 shows unique and novel features compared to its homologs. Serine substitution of residue F285, which harbors an aromatic side chain that disturbs RNA binding compared with other homologs, increases catalytic activity. Mutations of residues residing on the oligomerization interfaces that distort hexamerization, namely, N38A, Y58A and N157A, decrease thermostability, decrease binding affinity with RNA and reduce the NendoU activity of Nsp15. In contrast, mutant D39A exhibits increased activity and a higher substrate binding capacity. Importantly, Nsp8 is found to interact with both monomeric and hexameric Nsp15. The Nsp7/Nsp8 complex displays a higher binding affinity for Nsp15. Furthermore, Nsp8 and the Nsp7/Nsp8 complex also enhance the NendoU activity of hexameric Nsp15 in vitro Taken together, this work first provides evidence on how the activity of Nsp15 may be functionally mediated by catalytic residues, oligomeric assembly, RNA binding efficiency or the possible association with other non-structural proteins.IMPORTANCEThe lethally pathogenic Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus (SARS-CoV) pose serious threats to humans. Endoribonuclease Nsp15 encoded by coronavirus plays an important role in viral infection and pathogenesis. This study determines the structure of MERS-CoV Nsp15 and demonstrates how the catalytic activity of this protein is potentially mediated, thereby providing structural and functional evidence for developing antiviral drugs. We also hypothesize that the primase-like protein Nsp8 and Nsp7/Nsp8 complex may interact with Nsp15 and affect enzymatic activity. This contributes to the understanding of the association of Nsp15 with the viral replication and transcription machinery. | |||
Structural and biochemical characterization of endoribonuclease Nsp15 encoded by Middle East respiratory syndrome coronavirus.,Zhang L, Li L, Yan L, Ming Z, Jia Z, Lou Z, Rao Z J Virol. 2018 Aug 22. pii: JVI.00893-18. doi: 10.1128/JVI.00893-18. PMID:30135128<ref>PMID:30135128</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 5yvd" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Mers]] | |||
[[Category: Yan, L]] | [[Category: Yan, L]] | ||
[[Category: Zhang, L]] | [[Category: Zhang, L]] |
Revision as of 13:23, 5 September 2018
Structural highlights
Publication Abstract from PubMedNon-structural protein 15 (Nsp15) encoded by coronavirus (CoV) is a uridylate specific endoribonuclease (NendoU) that plays an essential role in the life cycle of the virus. Structural information of this crucial protein from the Middle East respiratory syndrome (MERS) CoV, which is lethally pathogenic and has caused severe respiratory diseases worldwide, is lacking. Here, we report the crystal structure of MERS-CoV Nsp15 at a 2.7 A resolution and perform the relevant biochemical assays to study how NendoU activity is regulated. Although the overall structure is conserved, MERS-CoV Nsp15 shows unique and novel features compared to its homologs. Serine substitution of residue F285, which harbors an aromatic side chain that disturbs RNA binding compared with other homologs, increases catalytic activity. Mutations of residues residing on the oligomerization interfaces that distort hexamerization, namely, N38A, Y58A and N157A, decrease thermostability, decrease binding affinity with RNA and reduce the NendoU activity of Nsp15. In contrast, mutant D39A exhibits increased activity and a higher substrate binding capacity. Importantly, Nsp8 is found to interact with both monomeric and hexameric Nsp15. The Nsp7/Nsp8 complex displays a higher binding affinity for Nsp15. Furthermore, Nsp8 and the Nsp7/Nsp8 complex also enhance the NendoU activity of hexameric Nsp15 in vitro Taken together, this work first provides evidence on how the activity of Nsp15 may be functionally mediated by catalytic residues, oligomeric assembly, RNA binding efficiency or the possible association with other non-structural proteins.IMPORTANCEThe lethally pathogenic Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus (SARS-CoV) pose serious threats to humans. Endoribonuclease Nsp15 encoded by coronavirus plays an important role in viral infection and pathogenesis. This study determines the structure of MERS-CoV Nsp15 and demonstrates how the catalytic activity of this protein is potentially mediated, thereby providing structural and functional evidence for developing antiviral drugs. We also hypothesize that the primase-like protein Nsp8 and Nsp7/Nsp8 complex may interact with Nsp15 and affect enzymatic activity. This contributes to the understanding of the association of Nsp15 with the viral replication and transcription machinery. Structural and biochemical characterization of endoribonuclease Nsp15 encoded by Middle East respiratory syndrome coronavirus.,Zhang L, Li L, Yan L, Ming Z, Jia Z, Lou Z, Rao Z J Virol. 2018 Aug 22. pii: JVI.00893-18. doi: 10.1128/JVI.00893-18. PMID:30135128[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
|